tirzepatide

Peptides

Tirzepatide's Expanding Frontier: Lipids, Brain Pressure, and a New Safety Signal

The dual GIP/GLP-1 agonist is moving past weight loss into lipid repair and intracranial pressure relief. But a small case series flags a risk off-label users haven't been warned about.

Peptides

Tirzepatide Without Diabetes: What the Meta-Analysis Behind the Hype Actually Shows

A new pooled analysis of randomized trials isolates the non-diabetic obesity population — the use case driving most consumer demand — and quantifies what the dual GIP/GLP-1 agonist actually does, and what it costs.